LEADER 03613nam 2200577Ia 450 001 9910437613903321 005 20200520144314.0 010 $a1-4614-6543-5 024 7 $a10.1007/978-1-4614-6543-0 035 $a(CKB)2550000001041782 035 $a(EBL)1205331 035 $a(SSID)ssj0000879291 035 $a(PQKBManifestationID)11442831 035 $a(PQKBTitleCode)TC0000879291 035 $a(PQKBWorkID)10851667 035 $a(PQKB)11718003 035 $a(DE-He213)978-1-4614-6543-0 035 $a(MiAaPQ)EBC1205331 035 $a(PPN)168305194 035 $a(EXLCZ)992550000001041782 100 $a20130228d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMHC class I antigens in malignant cells $eimmune escape and response to immunotherapy /$fNatalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera 205 $a1st ed. 2013. 210 $aNew York $cSpringer$dc2013 215 $a1 online resource (51 p.) 225 1 $aSpringerBriefs in cancer research ;$v6 300 $aDescription based upon print version of record. 311 $a1-4614-6542-7 327 $aOverview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion. 330 $aAbnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy.  Precise identification of the mechanism leading to MHC class I defects  will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy.  . 410 0$aSpringerBriefs in Cancer Research ;$v6. 606 $aOncology 606 $aImmunology 615 0$aOncology. 615 0$aImmunology. 676 $a616.99/4079 700 $aAptsiauri$b Natalia$01059918 701 $aGarcia-Lora$b Angel Miguel$01761872 701 $aCabrera$b Teresa$01761873 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437613903321 996 $aMHC class I antigens in malignant cells$94201552 997 $aUNINA